Host–microbe interaction: mechanisms of defensin deficiency in Crohn’s disease

References

• Boman HG. Peptide antibiotics and their role in innate immunity. Ann. Rev. Immunol.13, 61–92 (1995).
   PubMed Web of Science ®Google Scholar
• Zasloff M. Antimicrobial peptides of multicellular organisms. Nature415(6870), 389–395 (2002).
   PubMed Web of Science ®Google Scholar
• Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol.3(9), 710–720 (2003).
   PubMed Web of Science ®Google Scholar
• Dommett R, Zilbauer M, George JT, Bajaj-Elliott M. Innate immune defence in the human gastrointestinal tract. Mol. Immunol.42(8), 903–912 (2005).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease. J. Leukoc. Biol.77(4), 460–465 (2005).
   PubMed Web of Science ®Google Scholar
• Zasloff M. Antimicrobial peptides of multicellular organisms. Nature415(6870), 389–395 (2002).
   PubMed Web of Science ®Google Scholar
• Sallenave JM. Antimicrobial activity of antiproteinases. Biochem. Soc. Trans.30(2), 111–115 (2002).
   PubMed Web of Science ®Google Scholar
• Hiemstra PS. Novel roles of protease inhibitors in infection and inflammation. Biochem. Soc. Trans.30(2), 116–120 (2002).
   PubMed Web of Science ®Google Scholar
• Canny G, Cario E, Lennartsson A et al. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am. J. Physiol. Gastrointest. Liver Physiol.290(3), G557–G567 (2006).
   PubMed Web of Science ®Google Scholar
• Canny G, Levy O, Furuta GT et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl Acad. Sci. USA99(6), 3902–3907 (2002).
   PubMed Web of Science ®Google Scholar
• Simon GL, Gorbach SL. Normal alimentary tract microflora. In: Infections of the Gastrointestinal Tract. Blaser MJ, Smith PD, Ravdin HB, Greenberg RL, Guerrant RL (Eds). Raven Press, NY, USA 53–69 (1995).
   Google Scholar
• McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell. Microbiol.3(1), 1–11 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao C, Wang I, Lehrer RI. Widespread expression of β-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett.396(2–3), 319–322 (1996).
   PubMed Web of Science ®Google Scholar
• O’Neil DA, Porter EM, Elewaut D et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol.163(12), 6718–6724 (1999).
   PubMed Web of Science ®Google Scholar
• Cunliffe RN, Rose FR, Keyte J et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut48(2), 176–185 (2001).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Schmidt K, Herrlinger KR et al. Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status. J. Clin. Pathol.56(5), 352–357 (2003).
   PubMed Web of Science ®Google Scholar
• Shen B, Porter EM, Reynoso E et al. Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract. J. Clin. Pathol.58(7), 687–694 (2005).
   PubMed Web of Science ®Google Scholar
• Bevins CL. The Paneth cell and the innate immune response. Curr. Opin. Gastroenterol.20(6), 572–580 (2004).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Chu H, Shen B et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett.580(22), 5344–5350 (2006).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc. Natl Acad. Sci. USA102(50), 18129–18134 (2005).
   PubMed Web of Science ®Google Scholar
• Porter EM, Bevins CL, Ghosh D, Ganz T. The multifaceted Paneth cell. Cell Mol. Life Sci.59(1), 156–170 (2002).
   PubMed Web of Science ®Google Scholar
• Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature422(6931), 522–526 (2003).
   PubMed Web of Science ®Google Scholar
• Ayabe T, Satchell DP, Wilson CL et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol.1(2), 113–118 (2000).
   PubMed Web of Science ®Google Scholar
• Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host–microbial interactions and inflammatory disease. Ann. Rev. Biochem.74, 355–383 (2005).
   PubMed Web of Science ®Google Scholar
• Yang D, Chertov O, Bykovskaia SN et al. β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science286, 525–528 (1999).
   PubMed Web of Science ®Google Scholar
• Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell. Mol. Life Sci.58(7), 978–989 (2001).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Chamaillard M. NOD2 and defensins: translating innate to adaptive immunity in Crohn’s disease. J. Endotoxin Res.13(3), 135–139 (2007).
   PubMedGoogle Scholar
• Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis.62(Suppl. 2), II17–II21 (2003).
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med.347(6), 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Wilmanski JM, Petnicki-Ocwieja T, Kobayashi KS. NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J. Leukoc. Biol. (2007) DOI:10.1189/jlb.0607402 (Epub ahead of print).
   PubMedGoogle Scholar
• Gasche C, Grundtner P. Genotypes and phenotypes in Crohn’s disease: do they help in clinical management? Gut54(1), 162–167 (2005).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat. Rev. Genet.6(5), 376–388 (2005).
   PubMed Web of Science ®Google Scholar
• Schmid M, Fellermann K, Fritz P et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn’s disease. J. Leukoc. Biol.81(4), 907–915 (2007).
   PubMed Web of Science ®Google Scholar
• Schauber J, Rieger D, Weiler F et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol.18(6), 615–621 (2006).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M et al. Inducible and constitutive β-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis.9(4), 215–223 (2003).
   PubMed Web of Science ®Google Scholar
• Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin. Exp. Immunol.131(1), 90–101 (2003).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Fellermann K, Herrlinger KR et al. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol.14(7), 745–752 (2002).
   PubMed Web of Science ®Google Scholar
• Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. β-defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin. Exp. Immunol.137(2), 379–385 (2004).
   PubMed Web of Science ®Google Scholar
• Fellermann K, Stange DE, Schaeffeler E et al. A chromosome 8 gene-cluster polymorphism with low human β-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am. J. Hum. Genet.79(3), 439–448 (2006).
   PubMed Web of Science ®Google Scholar
• Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J. Microbiol. Methods65(2), 335–345 (2006).
   PubMed Web of Science ®Google Scholar
• Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut56(9), 1240–1247 (2007).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression. Gut53(11), 1658–1664 (2004).
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science307(5710), 731–734 (2005).
   PubMed Web of Science ®Google Scholar
• Tanabe H, Ayabe T, Maemoto A et al. Denatured human α-defensin attenuates the bactericidal activity and the stability against enzymatic digestion. Biochem. Biophys. Res. Commun.358(1), 349–355 (2007).
   PubMed Web of Science ®Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature434(7035), 843–850 (2005).
   PubMed Web of Science ®Google Scholar
• van Es JH, Jay P, Gregorieff A et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat. Cell Biol.7(4), 381–386 (2005).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Wang G, Kubler I et al. The Paneth cell α-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J. Immunol.179(5), 3109–3118 (2007).
   PubMed Web of Science ®Google Scholar
• Otto HF, Weitz H. Electron microscopy studies of Paneth cells in rats fed with zinc deficient diet. Beitr. Pathol.145(4), 336–349 (1972).
   PubMedGoogle Scholar
• Cousins RJ. A role of zinc in the regulation of gene expression. Proc. Nutr. Soc.57(2), 307–311 (1998).
   PubMed Web of Science ®Google Scholar
• Sazawal S, Black RE, Bhan MK et al. Zinc supplementation in young children with acute diarrhea in India. N. Engl. J. Med.333(13), 839–844 (1995).
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut54(1), 87–90 (2005).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Wehkamp K et al. NF-κB- and AP-1-mediated induction of human β defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun.72(10), 5750–5758 (2004).
   PubMed Web of Science ®Google Scholar
• Schlee M, Wehkamp J, Altenhoefer A et al. Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun.75(5), 2399–2407 (2007).
   PubMed Web of Science ®Google Scholar
• Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol. Ther.11(5), 853–858 (1997).
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut53(11), 1617–1623 (2004).
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet354(9179), 635–639 (1999).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Fellermann K, Herrlinger K, Bevins C, Stange EF. Mechanisms of disease: defensins in gastrointestinal diseases. Nat. Clin. Pract.2, 406–415 (2005).
   Google Scholar